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Pharmaceuticals in LaJolla, California. For
purposes of the study, the researchers
defined pesticide exposure as pesticide use
for more than 20 days in any given year, a
level they say is based on typical use ofthe
chemicals in commercial grain farming.
The allele in question activates a series of
enzymes in the liver that metabolize and
detoxify chemicals that enter the body.
However, up to 10% ofCaucasians have a
mutant version of the allele, which results
in no activity of this enzyme system. The
hypothesis is that such people might be
particularly susceptible to environmental
toxicants because of their inability to
detoxify chemicals.
While provocative, this study does
have some important limitations. Its
case-control design is less than ideal for
studying risk factors in Parkinson's dis-
ease, because symptoms of the disease
may change over time. Thus, some ofthe
subjects in the no-dementia control
group may later develop dementia.
Another drawback is the study's reliance
on self-reports from dementia patients.
Yet another concern is "the absence of
predictive value for either pesticide expo-
sure or the allele taken alone," says Jean
Harry, a group leader in the
NIEHS Environmental Toxi-
cology Program. Only the inter-
action between these variables
was statistically significant. In
addition, Harry notes that the
study used "a crude estimate of
pesticide exposure." Still, she
says, the results offer interesting
data for further evaluation.
Clearly, the gene-toxicant
interaction still needs to be con-
firmed by further research, ideal-
ly a larger, prospective study of
Parkinson's-related dementia. Several pre-
vious studies found an association between
Parkinson's disease and pesticides, other
toxicants, and rural living, but so far no
specific pesticide or class ofenvironmental
toxicants has been definitively linked to
the disease. "Overall, past studies support
the notion that pesticide exposure is a risk
factor for Parkinson's disease, but only in
a subset of individuals," says Kurth. In
fact, he says, "Most Parkinson's patients
do not have a history of pesticide expo-
sure, and the recognition of Parkinson's
disease predates the development of these
compounds." The gene-toxicant interac-
tion is another tantalizing clue in the
quest for the causes of Parkinson's disease
in its various forms, but only time will tell
whether it is a true clue or a red herring.
5r K FJGenetic Toolbox
As the Human Genome Project steadily rolls forward, much of the information on
human chromosomes is being catalogued in digital databases such as GenBank, which
now contains well over 141 million base pairs' worth ofinformation on human DNA.
The problem facing scientists now is not so much how to gather genetic information,
but-rather how to take advantage ofthe data that have already been harvested. This is where
researchers such as Harold "Skip" Garner are trying to make a difference. With the help ofa
Hewlett-Packard supercomputer and theWorld WideWeb, Garner and his colleagues at the
University ofTexas Southwestern Medical Center in Dallas are gathering useful information
from GenBankand making itavailable to researchers across theglobe.
Especially interesting to scientists that studygenetically influenced diseases are the pieces
ofhuman DNA that tend to vary among individuals. Differences in these regions-called
polymorphisms-can be telltale signs that a person carries a genetic disease or is genetically
susceptible to getting a disease. Because GenBank contains manyduplicate bits ofDNAdata
that come from the same part ofthe samechromosome but from different individuals, analy-
sis ofthedatabasecanshowwherepolymorphisms tendto occur.
Gleaning the locations ofpolymorphisms from the data in GenBank is the purpose of
the Polymorphic Marker Predictions ofUbiquitous Simple Sequences, or POMPOUS, a
suite ofcomputer programsdesigned byGarnerandhiscolleagues. Thus far, POMPOUS has
found 13,261 polymorphic regions in the human genome. Information about these regions,
including their nudeotide sequences, is available on the Garner laboratory home page at
http://pompous.swmed.edu.
Bydickingthe POMPOUS linkon the Garnerhomepageand then
following the link named Analysis ofYour Sequence by POMPOUS
Server, researchers can'also make use ofthesupercomputer's eight proces-
sors and 0.5 gigabytes ofRAM to compare their own data to GenBank.
Not onlywill the computer find known polymorphic regions in the sup-
plied DNAsequence (up to 32,000 baseslong), itwill also return apairof
primers for each. Primers are unique DNA sequences used to isolate the
polymorphic region for further study. In a test of the software,
POMPOUS identified 33 polymorphic regions in a part of a human
chromosome implicated in breast and lung cancer. Twenty-two ofthese
wereshown to actuallyvaryin agroup of36 cancerpatients.
Other software tools for genetic researchers are also available from
the Garner site. These can be accessed by following the Computational
Biologylink on thehome page. One ofthesetools, GeneAlert, assists researcherswho are ana-
lyzing aknown sequenceofDNAusingthe National Centerfor BiotechnologyInformation's
BLAST programs. GeneAlert will automatically pare down the often exhaustive lists of
matching DNA sequences returned from such a search to only those that are relevant, for
instance, only those containing a certain keyword such as "human" or "carcinoma." Another
software tool available at this site is SIGNAL, aprogram that can be downloaded and used to
make comparisons between DNA and protein sequences. Other tools, induding a complex
and thorough genehuntingsystem, areplannedforinclusion on thesite in thefuture.
Another highlight ofthe Garner site is the information on biochips available by fol-
lowing the Chip Based & Nanovolume Biology link. The chips are a promising new
technology for sorting DNAsamples so that their nucleotide sequences can be identified.
A biochip contains an array of tiny, segregated spots, each with its own sequence of
nudeotides. The nucleotide sequences on the biochip, to which the sample DNA strands
bond, can be constructed by controlling the reagents and the amount oflight that reaches
each spot on thechip during construction. Currently, the Garnerlaboratory is experimenting
with a light processing microchip and a reagent delivery system thatwill allow the researchers
to build chips with up to 2 million unique spots. Such chips may be able to efficiendy diag-
nose geneticdiseases andidentifymedicallyrelevant genes.
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